Qiagen (NYSE:QGEN) Releases Q1 2025 Earnings Guidance

Qiagen (NYSE:QGEN) updated its first quarter 2025 earnings guidance on Monday. The company provided EPS guidance of 0.550- for the period, compared to the consensus EPS estimate of 0.490. The company issued revenue guidance of $483.0 million-, compared to the consensus revenue estimate of $464.8 million. Qiagen also updated its FY 2025 guidance to 2.350- EPS.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on QGEN shares. Robert W. Baird lowered shares of Qiagen from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $52.00 to $42.00 in a research report on Wednesday, February 19th. Baird R W downgraded shares of Qiagen from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 19th. Morgan Stanley reaffirmed an “equal weight” rating and set a $46.67 price target (down from $48.61) on shares of Qiagen in a research report on Monday, January 6th. Jefferies Financial Group reaffirmed a “buy” rating and set a $52.50 price objective (up previously from $40.83) on shares of Qiagen in a research note on Tuesday, December 10th. Finally, UBS Group dropped their price target on shares of Qiagen from $50.00 to $48.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Eight investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $47.71.

Qiagen Stock Performance

QGEN opened at $38.24 on Monday. The firm’s fifty day simple moving average is $40.27 and its two-hundred day simple moving average is $41.94. Qiagen has a 52-week low of $37.63 and a 52-week high of $49.30. The company has a market cap of $8.50 billion, a price-to-earnings ratio of 106.48, a PEG ratio of 2.39 and a beta of 0.62. The company has a quick ratio of 3.09, a current ratio of 3.61 and a debt-to-equity ratio of 0.38.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. Equities analysts anticipate that Qiagen will post 2.26 earnings per share for the current fiscal year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.